BioLineRx to Report 2021 Annual Results on March 16, 2022
BioLineRx Ltd. (NASDAQ: BLRX), a biopharmaceutical company focused on oncology, will release its audited financial results for the year ended December 31, 2021 on March 16, 2022, before market opening. A conference call featuring CEO Philip Serlin will occur on the same day at 10:00 a.m. EST. Investors can access a live webcast on the Investor Relations page. The company's lead drug, Motixafortide, is in advanced stages for various cancer treatments.
- None.
- None.
TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended December 31, 2021 on Wednesday, March 16, 2022, before the US markets open.
The Company will host a conference call on Wednesday, March 16, 2022 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until March 18, 2022; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.
The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, has successfully completed a pre-NDA meeting with the FDA, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.
BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.
For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.
Contact:
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com
or
Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2021-annual-results-on-march-16-2022-301499990.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx (BLRX) release its 2021 annual financial results?
What is the time of the BioLineRx earnings conference call?
Who will present at the BioLineRx earnings call?
How can I access the BioLineRx conference call?
What is Motixafortide being studied for?
